249 Characterization of unresectable and/or metastatic solid tumors patients treated with systemic anticancer therapy in first-line settings: a pan-tumor community-oncology based s... by Elise Wu, Alexander Spira, Sneha Sura

Editorial: Virtual patients and digital twins in the systems analysis of drug discovery and development by Chen Zhao, Hua He, Huilin Ma

Get full text

The epidemiologic burden of hepatitis C virus infection in Latin America by Shelagh M. Szabo, Meagan Bibby, Yong Yuan, Bonnie M.K. Donato, R. Jiménez-Mendez, G. Castañeda-Hernández, Maribel Rodríguez-Torres, Adrian R. Levy

Get full text

Immunogenicity to Biotherapeutics – the role of Anti-drug Immune complexes by Murli eKrishna, Steven eNadler

Get full text

S188: CAR-T CELLS SHAPE THE IMMUNOLOGICAL POTENTIAL OF THE TUMOR MICROENVIRONMENT by Julia Frede, Julia Poller, Kayleen Shi, Hannah Stuart, Noori Sotoudeh, Klothilda Lim, Caroline Wiggers, Johannes Waldschmidt, Valeriya Dimitrova, Anna Montanaro, Eugene Cho, Tushara Vijaykumar, Paul Richardson, Nikhil Munshi, Kenneth Anderson, Nathan Martin, Shari Kaiser, Marc-Steffen Raab, Birgit Knoechel, Jens Lohr

Get full text

Calibration and validation of the rabbit model of electrolytic‐mediated arterial thrombosis against the standard‐of‐care anticoagulant apixaban by Pancras C. Wong, Earl Crain

Get full text

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis by Robert J. Fox, Rina Mehta, Timothy Pham, Julie Park, Kathleen Wilson, Machaon Bonafede

Get full text

Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis by Kabirraaj Toor, Mark R. Middleton, Keith Chan, Adenike Amadi, Andriy Moshyk, Srividya Kotapati

Get full text

Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors by Suthee Rapisuwon, Benjamin Izar, Cory Batenchuk, Alexandre Avila, Shaolin Mei, Peter Sorger, Jerry M. Parks, Sarah J. Cooper, David Wagner, Jay C. Zeck, Aline J. Charabaty, Michael B. Atkins

Get full text

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany by Tjalf Ziemssen, Stephan Richter, Mathias Mäurer, Mathias Buttmann, Boris Kreusel, Anne-Maria Poehler, Maren Lampl, Ralf A. Linker

Get full text

Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe by Verleger K, Penrod JR, Manley Daumont M, Solem C, Luo L, Macahilig C, Hertel N

“…Katharina Verleger, 1 John R Penrod, 2 Melinda Manley Daumont, 3 Caitlyn Solem, 4 Linlin Luo, 4 Cynthia Macahilig, 5 Nadine Hertel 6 1Pharmerit International, Berlin, Germany; 2Bristol-Myers Squibb, Princeton, NJ, USA; 3Bristol-Myers Squibb, Braine-L’alleud, Belgium; 4Pharmerit International, Bethesda, MD, USA; 5Medical Data Analytics, Parsippany, NJ, USA; 6Bristol-Myers Squibb, Uxbridge, UKCorrespondence: Katharina VerlegerPharmerit International, Krausenstr 8, Berlin 10117, GermanyTel +49 30 3080 7024Email kverleger@pharmerit.comPurpose: Advanced non-small-cell lung cancer (aNSCLC; stage IIIB/IV) presents a substantial clinical burden to society; reliable estimates of its economic burden are lacking. …”
Get full text

Poor Patient-Reported Outcomes and Impaired Work Productivity in Patients With Inflammatory Bowel Disease in Remission by Raymond K. Cross, Jenny S. Sauk, Joe Zhuo, Ryan W. Harrison, Samantha J. Kerti, Kelechi Emeanuru, Jacqueline O’Brien, Harris A. Ahmad, Antoine G. Sreih, Joehl Nguyen, Sara N. Horst, David Hudesman

Get full text

Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical tr... by Takayuki Yoshino, Josep Tabernero, Jin Yao, Amit Mahipal, Eric Chen, Heinz-Josef Lenz, Aparna Parikh, Timothy Larson, Dustin Deming, David R Spigel, Allen L Cohn, Mark Kochenderfer, Elena Elez, Spencer H Shao, Regan Holdridge, Antonio Ucar, Dana Cullen, Edwina Baskin-Bey, Tong Kang, Amy B Hammell

Get full text

A PHASE 3, TWO-STAGE, RANDOMIZED STUDY OF MEZIGDOMIDE, CARFILZOMIB, AND DEXAMETHASONE (MEZIKD) VERSUS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR... by PGR Md, MA Phd, JRB Md, CCM Phd, MAD Md, CTH Md, JKM Phd, AOM Phd, RZOM Phd, Md HQ, MSR Md, ARM Phd, DW Md, ZZ Phd, VHM Phd, JKM Phd

Get full text

113 Development of T cell-based immunotherapies to target dormant disseminated breast cancer cells by Stanley Riddell, Shivani Srivastava, Erica Goddard, Cyrus Ghajar

Regulation of microsomal triglyceride transfer protein mRNA expression by endotoxin and cytokines by Miguel Navasa, David A. Gordon, Narayanan Hariharan, Haris Jamil, Judy K. Shigenaga, Arthur Moser, Walter Fiers, Allan Pollock, Carl Grunfeld, Kenneth R. Feingold

Get full text

Uso de recursos sanitarios para tratar la leucemia mieloide crónica en Perú by Juan Navarro Cabrera, Carlos Carracedo Gonzáles, César Samanez Figari, Olga Vargas Castro, Cecilia Arteta Altamirano, Sebastián Garrido Lecca de la Piedra, Laura Jotimliansky

Get full text

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States by Daniel Kantor, Timothy Pham, Oscar Patterson-Lomba, Elyse Swallow, Akanksha Dua, Komal Gupte-Singh

Get full text

The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature by Bryan M. Bennett, Jane R. Wells, Charlotte Panter, Yong Yuan, John R. Penrod

Get full text

Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data by Teresa A. Simon, Lixian Dong, Kevin L. Winthrop

Get full text